BIG
TVTX icon

Brooklyn Investment Group’s Travere Therapeutics TVTX Stock Holding History

Brooklyn Investment Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,132
Closed -$150K – 1559
2025
Q3 		$150K Buy
10,132
+4,767
+89% +$89.6K 0.02% 619
2025
Q2 		$79.4K Buy
+5,365
New +$88.9K 0.01% 1073
2025
Q1 		– Sell
-401
Closed -$6.99K – 2887
2024
Q4 		$6.99K Buy
+401
New +$7.09K ﹤0.01% 1104

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brooklyn Investment Group's TVTX Position: Q4 2025 in Review

Brooklyn Investment Group sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 10,132 shares — an estimated $150K sold.

Brooklyn Investment Group first reported a position in TVTX in Q4 2024 and held it in 3 quarters. The position peaked at $150K in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Brooklyn Investment Group reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 10,132 Travere Therapeutics shares in Q4 2025, an estimated $150K.
  • Brooklyn Investment Group first reported a position in Travere Therapeutics in Q4 2024 and held it in 3 quarters.
  • Brooklyn Investment Group's Travere Therapeutics position peaked at $150K in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Brooklyn Investment Group's 13F filing for Q4 2025, filed 12 Feb 2026.